NCT04466475: Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma |
|
|
| Withdrawn | 1 | 30 | US | Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, 211At-OKT10-B10, [211At]OKT10-B10, Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10, Astatine At 211 Anti-CD38 MoAb OKT10-B10, Astatine-211-OKT10-B10, At211-OKT10-B10, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation | Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH) | Plasma Cell Myeloma | 10/25 | 09/27 | | |
NCT04579523: ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 30 | US | Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, ²¹¹At-OKT10-B10, [²¹¹At]OKT10-B10, Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10, Astatine At 211 Anti-CD38 MoAb OKT10-B10, Astatine-211-OKT10-B10, At211-OKT10-B10, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | 12/27 | 12/28 | | |